231 related articles for article (PubMed ID: 11669607)
1. Role of LMP1 in immune control of EBV infection.
Pai S; Khanna R
Semin Cancer Biol; 2001 Dec; 11(6):455-60. PubMed ID: 11669607
[TBL] [Abstract][Full Text] [Related]
2. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape.
Middeldorp JM; Pegtel DM
Semin Cancer Biol; 2008 Dec; 18(6):388-96. PubMed ID: 19013244
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
4. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
5. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
6. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
[TBL] [Abstract][Full Text] [Related]
7. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus.
Dirmeier U; Neuhierl B; Kilger E; Reisbach G; Sandberg ML; Hammerschmidt W
Cancer Res; 2003 Jun; 63(11):2982-9. PubMed ID: 12782607
[TBL] [Abstract][Full Text] [Related]
8. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus: exploiting the immune system.
Thorley-Lawson DA
Nat Rev Immunol; 2001 Oct; 1(1):75-82. PubMed ID: 11905817
[TBL] [Abstract][Full Text] [Related]
10. B cells under influence: transformation of B cells by Epstein-Barr virus.
Küppers R
Nat Rev Immunol; 2003 Oct; 3(10):801-12. PubMed ID: 14523386
[TBL] [Abstract][Full Text] [Related]
11. [Molecular biological properties of the Epstein-Barr virus LMP1 gene: structure, function and polymorphism].
Smirnova KV; Diduk SV; Senyuta NB; Gurtsevitch VE
Vopr Virusol; 2015; 60(3):5-13. PubMed ID: 26281300
[TBL] [Abstract][Full Text] [Related]
12. EBV latent membrane protein 1 is a negative regulator of TLR9.
Fathallah I; Parroche P; Gruffat H; Zannetti C; Johansson H; Yue J; Manet E; Tommasino M; Sylla BS; Hasan UA
J Immunol; 2010 Dec; 185(11):6439-47. PubMed ID: 20980631
[TBL] [Abstract][Full Text] [Related]
13. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
14. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease.
Meij P; Vervoort MB; Bloemena E; Schouten TE; Schwartz C; Grufferman S; Ambinder RF; Middeldorp JM
J Med Virol; 2002 Nov; 68(3):370-7. PubMed ID: 12226824
[TBL] [Abstract][Full Text] [Related]
15. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
Rechsteiner MP; Bernasconi M; Berger C; Nadal D
Trends Microbiol; 2008 Nov; 16(11):520-7. PubMed ID: 18835714
[TBL] [Abstract][Full Text] [Related]
16. Comparative proteomic analysis implicates COMMD proteins as Epstein-Barr virus targets in the BL41 Burkitt's lymphoma cell line.
Gkiafi Z; Panayotou G
J Proteome Res; 2011 Jul; 10(7):2959-68. PubMed ID: 21615174
[TBL] [Abstract][Full Text] [Related]
17. EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection.
van Gent M; Griffin BD; Berkhoff EG; van Leeuwen D; Boer IG; Buisson M; Hartgers FC; Burmeister WP; Wiertz EJ; Ressing ME
J Immunol; 2011 Feb; 186(3):1694-702. PubMed ID: 21191071
[TBL] [Abstract][Full Text] [Related]
18. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
19. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion.
Ho CH; Chen CL; Li WY; Chen CJ
Carcinogenesis; 2009 Aug; 30(8):1443-51. PubMed ID: 19483191
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody.
Piché A; Kasono K; Johanning F; Curiel TJ; Curiel DT
Gene Ther; 1998 Sep; 5(9):1171-9. PubMed ID: 9930317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
